Hans Joergen Grabe

Hans Joergen Grabe

Auto-generated profile, based on publicly available information

Hans Joergen Grabe

Department of Psychiatry and Psychotherapy, University Medicine Greifswald

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MCMDD Working Group of the Psychiatric Genomics Consortium
MDD Working Group of the Psychiatric Genomics Consortium
NCNa Cai
Na Cai
JRJoana A. Revez
Joana A. Revez
MAMark J. Adams
Mark J. Adams
TATill Andlauer
Till Andlauer
JFJonathan Flint
Jonathan Flint

18 May 2020 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
LHLaura K. M. Han
Laura K. M. Han
RDRichard Dinga
Richard Dinga
THTim Hahn
Tim Hahn
CCChristopher R. K. Ching
Christopher R. K. Ching
LELisa T Eyler
Lisa T Eyler
LSLianne Schmaal
Lianne Schmaal
Major depressive disorder (MDD) is associated with an increased risk of brain atrophy, aging-related diseases, and mortality. We examined potential advanced brain aging in adult MDD patients, and whether this process is associated with clinical characteristics in a large multicenter international dataset. We performed a mega-analysis by pooling brain measures derived from T1-weighted MRI scans from 19 samples worldwide. Healthy brain aging was estimated by predicting chronological age (18–75 years) from 7 subcortical volumes, 34 cortical thickness and 34 surface area, lateral ventricles and total intracranial volume measures separately in 952 male and 1236 female controls from the ENIGMA MDD working group. The learned model coefficients were applied to 927 male controls and 986 depressed males, and 1199 female controls and 1689 depressed females to obtain independent unbiased brain-based age predictions. The difference between predicted “brain age” and chronological age was calculated to indicate brain-predicted age difference (brain-PAD). On average, MDD patients showed a higher brain-PAD of +1.08 (SE 0.22) years (Cohen’s d = 0.14, 95% CI: 0.08–0.20) compared with controls. However, this difference did not seem to be driven by specific clinical characteristics (recurrent status, remission status, antidepressant medication use, age of onset, or symptom severity). This highly powered collaborative effort showed subtle patterns of age-related structural brain abnormalities in MDD. Substantial within-group variance and overlap between groups were observed. Longitudinal studies of MDD and somatic health outcomes are needed to further assess the clinical value of these brain-PAD estimates.

21 October 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CSClaudia L Satizabal
Claudia L Satizabal
HAHieab H H Adams
Hieab H H Adams
DHDerrek P Hibar
Derrek P Hibar
CWCharles C White
Charles C White
MKMaria J Knol
Maria J Knol
MIM Arfan Ikram
M Arfan Ikram

8 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMuralidharan Sargurupremraj
Muralidharan Sargurupremraj
HSHideaki Suzuki
Hideaki Suzuki
XJXueqiu Jian
Xueqiu Jian
CSChloe Sarnowski
Chloe Sarnowski
TETavia E. Evans
Tavia E. Evans
SDStéphanie Debette
Stéphanie Debette
White matter hyperintensities (WMH) are the most common brain-imaging feature of cerebral small vessel disease (SVD), hypertension being the main known risk factor. Here, we identify 27 genome-wide loci for WMH-volume in a cohort of 50,970 older individuals, accounting for modification/confounding by hypertension. Aggregated WMH risk variants were associated with altered white matter integrity (p = 2.5×10-7) in brain images from 1,738 young healthy adults, providing insight into the lifetime impact of SVD genetic risk. Mendelian randomization suggested causal association of increasing WMH-volume with stroke, Alzheimer-type dementia, and of increasing blood pressure (BP) with larger WMH-volume, notably also in persons without clinical hypertension. Transcriptome-wide colocalization analyses showed association of WMH-volume with expression of 39 genes, of which four encode known drug targets. Finally, we provide insight into BP-independent biological pathways underlying SVD and suggest potential for genetic stratification of high-risk individuals and for genetically-informed prioritization of drug targets for prevention trials.

29 May 2020 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
LSLianne Schmaal
Lianne Schmaal
EPElena Pozzi
Elena Pozzi
THTiffany C. Ho
Tiffany C. Ho
LVLaura S. van Velzen
Laura S. van Velzen
IVIlya M. Veer
Ilya M. Veer
DVDick J. Veltman
Dick J. Veltman
A key objective in the field of translational psychiatry over the past few decades has been to identify the brain correlates of major depressive disorder (MDD). Identifying measurable indicators of brain processes associated with MDD could facilitate the detection of individuals at risk, and the development of novel treatments, the monitoring of treatment effects, and predicting who might benefit most from treatments that target specific brain mechanisms. However, despite intensive neuroimaging research towards this effort, underpowered studies and a lack of reproducible findings have hindered progress. Here, we discuss the work of the ENIGMA Major Depressive Disorder (MDD) Consortium, which was established to address issues of poor replication, unreliable results, and overestimation of effect sizes in previous studies. The ENIGMA MDD Consortium currently includes data from 45 MDD study cohorts from 14 countries across six continents. The primary aim of ENIGMA MDD is to identify structural and functional brain alterations associated with MDD that can be reliably detected and replicated across cohorts worldwide. A secondary goal is to investigate how demographic, genetic, clinical, psychological, and environmental factors affect these associations. In this review, we summarize findings of the ENIGMA MDD disease working group to date and discuss future directions. We also highlight the challenges and benefits of large-scale data sharing for mental health research.

5 April 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
RBRachel M. Brouwer
Rachel M. Brouwer
MKMarieke Klein
Marieke Klein
KGKatrina Grasby
Katrina Grasby
HSHugo G. Schnack
Hugo G. Schnack
NJNeda Jahanshad
Neda Jahanshad
HPHilleke E. Hulshoff Pol
Hilleke E. Hulshoff Pol